Title: p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.
Journal: The Journal of pharmacology and experimental therapeutics 20120601
Title: DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular.
Journal: Clinical science (London, England : 1979) 20120501
Title: Mass balance, excretion and metabolism of [¹⁴C] ASA404 in cancer patients in a phase I trial.
Journal: Cancer chemotherapy and pharmacology 20120501
Title: Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.
Journal: British journal of cancer 20120313
Title: Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
Journal: Molecular cancer therapeutics 20120201
Title: High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery.
Journal: PloS one 20120101
Title: The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts.
Journal: BMC cancer 20120101
Title: Vascular disrupting agent drug classes differ in effects on the cytoskeleton.
Journal: PloS one 20120101
Title: Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging.
Journal: Angiogenesis 20111201
Title: Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice.
Journal: British journal of cancer 20111108
Title: Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation.
Journal: Biochemical pharmacology 20111101
Title: Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors.
Journal: Journal of cancer research and clinical oncology 20111101
Title: Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA).
Journal: Expert opinion on drug metabolism & toxicology 20111001
Title: Pharmacologic activation of the innate immune system to prevent respiratory viral infections.
Journal: American journal of respiratory cell and molecular biology 20110901
Title: The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors.
Journal: Japanese journal of clinical oncology 20110901
Title: Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110801
Title: Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110801
Title: Cardiovascular toxicity profiles of vascular-disrupting agents.
Journal: The oncologist 20110801
Title: Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents.
Journal: Human gene therapy 20110701
Title: Aminolevulinic acid-photodynamic therapy combined with topically applied vascular disrupting agent vadimezan leads to enhanced antitumor responses.
Journal: Photochemistry and photobiology 20110701
Title: Developing a robust ultrafiltration-LC-MS/MS method for quantitative analysis of unbound vadimezan (ASA404) in human plasma.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110701
Title: Clinical trials of vascular disrupting agents in advanced non--small-cell lung cancer.
Journal: Clinical lung cancer 20110501
Title: Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer.
Journal: Cancer science 20110401
Title: The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo.
Journal: Journal of leukocyte biology 20110301
Title: 18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110301
Title: Editorial: One small molecule: a new way to treat the flu?
Journal: Journal of leukocyte biology 20110301
Title: Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines.
Journal: Journal of biomedical science 20110101
Title: Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment.
Journal: BMC medical genomics 20110101
Title: Flavonoids: A versatile source of anticancer drugs.
Journal: Pharmacognosy reviews 20110101
Title: Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data.
Journal: Journal of thoracic disease 20101201
Title: Temporal aspects of the action of ASA404 (vadimezan; DMXAA).
Journal: Expert opinion on investigational drugs 20101101
Title: ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy.
Journal: Future oncology (London, England) 20101001
Title: Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action.
Journal: Neoplasia (New York, N.Y.) 20100901
Title: Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent.
Journal: British journal of cancer 20100824
Title: Vadimezan: 2-(5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid.
Journal: Acta crystallographica. Section E, Structure reports online 20100801
Title: RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline.
Journal: European radiology 20100601
Title: Guidelines for the welfare and use of animals in cancer research.
Journal: British journal of cancer 20100525
Title: Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100515
Title: Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.
Journal: Cancer 20100415
Title: Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).
Journal: The Journal of biological chemistry 20100402
Title: Novel agents target existing tumor vasculature.
Journal: Expert review of anticancer therapy 20100301
Title: [Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20100301
Title: The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
Journal: Expert opinion on investigational drugs 20100201
Title: Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound.
Journal: Journal of oncology 20100101
Title: Molecule of the month. Vadimezan.
Journal: Drug news & perspectives 20091101
Title: Molecular imaging of hypoxia with radiolabelled agents.
Journal: European journal of nuclear medicine and molecular imaging 20091001
Title: AVE8062: a new combretastatin derivative vascular disrupting agent.
Journal: Expert opinion on investigational drugs 20091001
Title: Acute vascular disruption by 5,6-dimethylxanthenone-4-acetic Acid in an orthotopic model of human head and neck cancer.
Journal: Translational oncology 20090818
Title: Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands) 20090801
Title: MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas.
Journal: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20090801
Title: Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404).
Journal: Neoplasia (New York, N.Y.) 20090801
Title: Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs.
Journal: Investigational new drugs 20090601
Title: Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.
Journal: Investigative ophthalmology & visual science 20090601
Title: Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.
Journal: The oncologist 20090601
Title: The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo.
Journal: Photochemistry and photobiology 20090101
Title: Immune-modulating and anti-vascular activities of two xanthenone acetic acid analogues: A comparative study to DMXAA.
Journal: International journal of oncology 20090101
Title: Indexing TNF-alpha gene expression using a gene-targeted reporter cell line.
Journal: BMC biology 20090101
Title: Zolpidem, a clinical hypnotic that affects electronic transfer, alters synaptic activity through potential GABA receptors in the nervous system without significant free radical generation.
Journal: Oxidative medicine and cellular longevity 20090101
Title: Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
Journal: British journal of cancer 20081209
Title: Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors.
Journal: International journal of radiation oncology, biology, physics 20081115
Title: ASA404: update on drug development.
Journal: Expert opinion on investigational drugs 20081001
Title: [Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Journal: Magyar onkologia 20080901
Title: Vessel size index magnetic resonance imaging to monitor the effect of antivascular treatment in a rodent tumor model.
Journal: International journal of radiation oncology, biology, physics 20080801
Title: Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways.
Journal: Journal of immunology (Baltimore, Md. : 1950) 20080515
Title: Exploration of the mechanism underlying the tumor necrosis avidity of hypericin.
Journal: Oncology reports 20080401
Title: Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080401
Title: Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
Journal: Cancer chemotherapy and pharmacology 20080301
Title: IFN-beta-dependent inhibition of tumor growth by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Journal: Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20080301
Title: The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer.
Journal: Expert opinion on investigational drugs 20080101
Title: The ability of coumarin-, flavanon- and flavonol-analogues of flavone acetic acid to stimulate human monocytes.
Journal: Oncology reports 20080101
Title: Molecular profiling of angiogenesis in hypericin mediated photodynamic therapy.
Journal: Molecular cancer 20080101
Title: The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours.
Journal: Acta oncologica (Stockholm, Sweden) 20080101
Title: Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
Journal: International journal of radiation oncology, biology, physics 20071115
Title: Early experience with novel immunomodulators for cancer treatment.
Journal: Expert opinion on investigational drugs 20070901
Title: Synthesis and biological activity of azido analogues of 5,6-dimethylxanthenone-4-acetic acid for use in photoaffinity labeling.
Journal: Journal of medicinal chemistry 20070809
Title: The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes.
Journal: Cancer research 20070715
Title: The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.
Journal: The Journal of experimental medicine 20070709
Title: N-(4-iodophenyl)-N'-(2-chloroethyl)urea as a microtubule disrupter: in vitro and in vivo profiling of antitumoral activity on CT-26 murine colon carcinoma cell line cultured and grafted to mice.
Journal: British journal of cancer 20070604
Title: Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Journal: Investigational new drugs 20070601
Title: Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of DMXAA in human and mouse plasma.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070601
Title: Vascular disrupting agents in clinical development.
Journal: British journal of cancer 20070423
Title: Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours.
Journal: Cancer chemotherapy and pharmacology 20070401
Title: Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial.
Journal: Cancer chemotherapy and pharmacology 20070401
Title: Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome.
Journal: Neoplasia (New York, N.Y.) 20070201
Title: DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.
Journal: British journal of cancer 20070129
Title: NF-kappaB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA.
Journal: Anticancer research 20070101
Title: Oxygen sensitivity of reporter genes: implications for preclinical imaging of tumor hypoxia.
Journal: Molecular imaging 20070101
Title: Vascular disrupting agents.
Journal: Journal of cellular biochemistry 20061101
Title: 5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapy.
Journal: Immunology and cell biology 20060801
Title: Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts.
Journal: Neoplasia (New York, N.Y.) 20060701
Title: New derivatives of xanthenone-4-acetic acid: synthesis, pharmacological profile and effect on TNF-alpha and NO production by human immune cells.
Journal: Bioorganic & medicinal chemistry 20060615
Title: Current development status of small-molecule vascular disrupting agents.
Journal: Current opinion in investigational drugs (London, England : 2000) 20060601
Title: 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20060315
Title: Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.
Journal: Neoplasia (New York, N.Y.) 20060301
Title: The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.
Journal: Acta oncologica (Stockholm, Sweden) 20060101
Title: Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors.
Journal: Oncology research 20060101
Title: Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Journal: Cancer research 20051215
Title: Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005?
Journal: Clinical lung cancer 20051101
Title: Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI.
Journal: British journal of cancer 20051031
Title: Fundamental, electron transfer mechanism by pyrylium-type ions for the anticancer drugs 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA).
Journal: Current medicinal chemistry. Anti-cancer agents 20050901
Title: Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability.
Journal: International journal of cancer 20050820
Title: Inhibition of human CYP1A2 oxidation of 5,6-dimethyl-xanthenone-4-acetic acid by acridines: a molecular modelling study.
Journal: Clinical and experimental pharmacology & physiology 20050801
Title: Disrupting tumour blood vessels.
Journal: Nature reviews. Cancer 20050601
Title: Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20050601
Title: Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20050515
Title: The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.
Journal: British journal of cancer 20050509
Title: Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20050401
Title: Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.
Journal: Current oncology reports 20050301
Title: Mono- or di-fluorinated analogues of flavone-8-acetic acid: synthesis and in vitro biological activity.
Journal: Anticancer research 20050101
Title: A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kappaB in murine and human cell lines.
Journal: Oncology research 20050101
Title: Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040925
Title: Vascular-targeting therapies for treatment of malignant disease.
Journal: Cancer 20040615
Title: Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
Journal: International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20040601
Title: Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
Journal: Cancer chemotherapy and pharmacology 20040501
Title: Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites.
Journal: Biochemical pharmacology 20040301
Title: Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice.
Journal: British journal of cancer 20040223
Title: Vascular targeting agents as cancer therapeutics.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20040115
Title: Angiogenesis inhibitors in clinical development; where are we now and where are we going?
Journal: British journal of cancer 20040112
Title: Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20031215
Title: Clostridia in cancer therapy.
Journal: Nature reviews. Microbiology 20031201
Title: Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
Journal: Cancer research 20031115
Title: Synthesis and biological evaluation of 3-alkoxy analogues of flavone-8-acetic acid.
Journal: Journal of medicinal chemistry 20030814
Title: Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.
Journal: British journal of cancer 20030804
Title: Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.
Journal: British journal of cancer 20030616
Title: Requirements for ICAM-1 immunogene therapy of lymphoma.
Journal: Cancer gene therapy 20030601
Title: Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Journal: Biochemical pharmacology 20030601
Title: Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging.
Journal: British journal of cancer 20030519
Title: NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Journal: European journal of cancer (Oxford, England : 1990) 20030501
Title: 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study.
Journal: British journal of cancer 20030422
Title: Early detection of tumour immune-rejection using magnetic resonance imaging.
Journal: British journal of cancer 20030407
Title: The first international conference on vascular targeting: meeting overview.
Journal: Cancer research 20030301
Title: Antivascular therapy of cancer: DMXAA.
Journal: The Lancet. Oncology 20030301
Title: Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Journal: Biochemical pharmacology 20030101
Title: Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Journal: Cancer chemotherapy and pharmacology 20030101
Title: Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Journal: Oncology research 20030101
Title: DMXAA: an antivascular agent with multiple host responses.
Journal: International journal of radiation oncology, biology, physics 20021201
Title: Combination of vascular targeting agents with thermal or radiation therapy.
Journal: International journal of radiation oncology, biology, physics 20021201
Title: Enhancement of radiation therapy by vascular targeting agents.
Journal: Current opinion in investigational drugs (London, England : 2000) 20021101
Title: Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.
Journal: Drug metabolism reviews 20021101
Title: Synthesis and antitumor activity of new derivatives of xanthen-9-one-4-acetic acid.
Journal: Journal of medicinal chemistry 20021024
Title: Potential of DMXAA combination therapy for solid tumors.
Journal: Expert review of anticancer therapy 20021001
Title: An improved synthesis of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Journal: European journal of medicinal chemistry 20021001
Title: Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020915
Title: Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020905
Title: The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
Journal: British journal of cancer 20020812
Title: 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
Journal: Investigational new drugs 20020801
Title: Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species.
Journal: The Journal of pharmacy and pharmacology 20020701
Title: Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid.
Journal: British journal of cancer 20020617
Title: A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.
Journal: British journal of cancer 20020520
Title: Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy.
Journal: International journal of cancer 20020501
Title: Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy.
Journal: Neoplasia (New York, N.Y.) 20020501
Title: Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS.
Journal: NMR in biomedicine 20020401
Title: Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis.
Journal: NMR in biomedicine 20020401
Title: High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020205
Title: Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Journal: Cancer chemotherapy and pharmacology 20020201
Title: Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20020201
Title: Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
Journal: Cancer chemotherapy and pharmacology 20020101
Title: Thalidomide in cancer treatment: a potential role in the elderly?
Journal: Drugs & aging 20020101
Title: 6-methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3.
Journal: European journal of drug metabolism and pharmacokinetics 20020101
Title: Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines.
Journal: Oncology research 20020101
Title: Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.
Journal: Clinica chimica acta; international journal of clinical chemistry 20011201
Title: Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid.
Journal: Radiation research 20011101
Title: The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor.
Journal: European journal of cancer (Oxford, England : 1990) 20011001
Title: Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.
Journal: British journal of clinical pharmacology 20010801
Title: Small-molecule cytokine inducers causing tumor necrosis.
Journal: Current opinion in investigational drugs (London, England : 2000) 20010701
Title: Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography.
Journal: Journal of chromatography. B, Biomedical sciences and applications 20010615
Title: Determination of unbound concentration of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in human plasma by ultrafiltration followed by high-performance liquid chromatography with fluorimetric detection.
Journal: Journal of chromatography. B, Biomedical sciences and applications 20010615
Title: Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Journal: Cancer chemotherapy and pharmacology 20010601
Title: A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
Journal: Cancer chemotherapy and pharmacology 20010601
Title: Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20010501
Title: Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species.
Journal: The Journal of pharmacy and pharmacology 20010401
Title: In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
Journal: Cancer chemotherapy and pharmacology 20010401
Title: Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Journal: Cancer research 20010301
Title: Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Journal: Cancer research 20010215
Title: Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.
Journal: International journal of radiation biology 20010201
Title: Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
Journal: International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20010101
Title: Downey CM, et al. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization. PLoS One. 2014 Jun 18;9(6):e99988.
Title: Shirey KA, et al. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. J Leukoc Biol. 2011 Mar;89(3):351-7.
